SILu™MAb Infliximab Stable-Isotope Labeled Monoclonal Antibody
SIGMA/MSQC9 - recombinant, expressed in CHO cells
Synonym: Mass spectrometry standard, Infliximab; SIL Infliximab; Stable isotope labelled Infliximab
Product Type: Chemical
SILu™MAb Infliximab Stable-Isotope Labeled Universal Monoclonal Antibody, Cat. No. MSQC9: Extracted ion chromatogram (XIC) of representative peptides from the digested SILuMAb Infliximab. This internal standard enables sensitive, accurate, and reproducible quantification Infliximab.
| antibody product type | primary antibodies |
| assay | ≥90% (SDS-PAGE) |
| packaging | vial of 100 μg |
| Quality Level | 200  |
| recombinant | expressed in CHO cells |
| shipped in | wet ice |
| storage temp. | −20°C |
| Analysis Note: | Quantitative MRM settings provided (xls ) |
| Application: | Poster: Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard |
| General description: | SILu™MAb Infliximab Stable-Isotope Labeled Monoclonal Antibody (MSQC9) is a recombinant, stable isotope-labeled, monoclonal antibody which incorporates [13C6, 15N4]-Arginine and [13C6, 15N2]-Lysine. Expressed in CHO cells, it is designed to be used as an internal standard for the quantitative mass spectrometry analysis of Infliximab in human serum. Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-a) and is used to treat autoimmune diseases. Infliximab has been approved for the treatment of Crohn′s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. SILu™MAb Infliximab Stable-Isotope Labeled Monoclonal Antibody is for R&D use only. Not for drug, household, or other uses. |
| Legal Information: | SILu is a trademark of Sigma-Aldrich Co. LLC |
| Legal Information: | This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com. |
| Physical form: | Each vial of SILu™Mab Infliximab Stable-Isotope Labeled Monoclonal Antibody contains the labeled antibody in a lyophilized form containing phosphate buffered saline. |
| Preparation Note: | Produced utilizing enriched media containing stable isotope labeled amino acids are 13C6, 15N4-labeled Arginine and 13C6, 15N2-labeled Lysine. |
| Preparation Note: | SILu™Mab Infliximab recovery is maximized when 0.1% formic acid is used for reconstitution of the lyophilized product.Reconstitution with other solvents may reduce recovery. Do not freeze after reconstitution. • Briefly centrifuge the vial at ~10,000 × g to collect the product at the bottom of the vial. • Add 500 μL of ultrapure water containing 0.1% formic acid to the vial. • Mix the contents by gently inverting the vial a minimum of 5 times. • Allow the vial to stand at room temperature for at least 15 minutes and repeat mixing by inversion. |
| Preparation Note: | SILu™Mab Infliximab Stable-Isotope Labeled Monoclonal Antibody is designed to be used as a internal standard for analysis of Infliximab in human serum. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥90% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |